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Rosuvastatin improves vascular function of
arteriovenous fistula in a diabetic rat model
Jun-Neng Roan, MD,a,b Shih-Yuan Fang, MD,c Shih-Wei Chang, BS,c,d Chih-Hsin Hsu, MD,a,e
Chein-Chi Huang, MS,c Meng-Hsuan Chiou, MS,c Yu-Chuan Tsai, MD,c and
Chen-Fuh Lam, MD, PhD,c Tainan, Taiwan
Objective:This study investigates the pathogenesis of arteriovenous (AV) fistula failure in patients with diabetesmellitus (DM)
and tests the vascular protective effect of rosuvastatin on the fistulous communication of diabetic rats.
Methods:DMwas induced in rats by a single injection of streptozotocin. One week later, a fistula was created in the descending
aorta and the adjacent inferior vena cava (aortocaval [AC] fistula). Rats were then randomly assigned to receive placebo or
rosuvastatin (15 mg/kg/d) in chow for 2 weeks. Blood flow in the aortic segments of the fistula was measured. Circulating
CD34/KDR endothelial progenitor cells (EPCs) were determined 2 weeks after creation of the AC fistulas using flow
cytometry. Vascular function of the AC fistulas was assessed by isometric force testing. The expression of proinflammatory
genes and generation of superoxide anions in the fistulas were examined.
Results:The number of EPCswas reduced in diabetic rats, and rosuvastatin significantly increased the number of circulating EPCs.
Reduced blood flow and impaired endothelium-dependent relaxation in the AC fistula of animals with diabetes was significantly
potentiated after treatment with rosuvastatin. Rosuvastatin also attenuated the expression of inducible nitric oxide synthase and
nicotinamideadeninedinucleotidephosphateoxidase andgenerationof superoxideanions in thefistula tissues isolated fromdiabetic
rats.
Conclusions:We provide the first evidence demonstrating that rosuvastatin improves blood flow and endothelial function of
AC fistulas in rats with DM by attenuating the activity of proinflammatory genes and generation of superoxide anions in the
remodeled vasculature. (J Vasc Surg 2012;56:1381-9.)
Clinical Relevance: Arteriovenous (AV) fistula is the most common vascular access for hemodialysis in patients with
end-stage renal disease. Studies have shown that blood flow in the AV fistula is significantly reduced in patients with
diabetes and the period for maturation of an AV fistula is longer in these patients. The underlying mechanisms of AV
fistula failure in diabetes are still poorly understood and there are limited therapeutic approaches that can increase the
lifespan of these fistulas. The present study demonstrates that oral administration rosuvastatin improves blood flow and
endothelial function of AC fistulas in rats with diabetes, which results from attenuating the activity of proinflammatory
genes in the remodeled vasculature, thereby reducing the generation of tissue superoxide anions. Our results may thus
enhance our ability to prevent and manage vascular access failure in patients with diabetes with chronic renal disease.
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aHemodialysis is currently the main therapy of renal re-
placement therapy for patients with end-stage renal disease
(ESRD). In Taiwan, diabetic nephropathy is the second most
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http://dx.doi.org/10.1016/j.jvs.2012.03.243ommon cause of ESRD, but patients with diabetes engender
2% more expense for care of dialysis than patients who are
ondiabetic.1 Hemodialysis necessitates the creation of an
rteriovenous (AV) fistula in native vessels or placement of a
ynthetic graft or catheter. The procedures for creating theAV
stula and treatment of the related complication account for
ver 20% of hospitalizations of patients receiving dialysis and
ost about $100 million U.S. dollars annually.2 Two major
urdles in establishing a usable and patent AV fistula for
ialysis are primary failure (failure of fistula to mature ade-
uately for dialysis) and long-term survival of the vascular
ccess.2 It has been shown that reduction of blood flow is an
mportant factor contributing to failure of an AV fistula.3
lthough blood flow in the venous site of an AV fistula is also
eterminedby the surroundingdraining veins, bloodpumped
rom the arterial site is the most important factor in maintain-
ng sufficient fistula blood flow.However, very limited studies
ave reported the effect of arterial blood flow on the function
nd patency of an AV fistula, particularly in patients with
iabetes.
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November 20121382 Roan et alHyperglycemia has been known to increase vascular
oxidative stress and causes endothelial dysfunction.4 There
are also extensive data indicating that hyperglycemia en-
hances release of proinflammatory cytokines, which may
exacerbate inflammatory reaction in the vasculature of fis-
tulas. Some studies showed that blood flow in the AV fistula
is significantly reduced in patients with diabetes mellitus
(DM).5,6 Patients with diabetes also require a significantly
longer period of time for the maturation of AV fistulas and
have higher complication rates than patients who are non-
diabetic.7,8
The 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitor (statins) are the most commonly prescribed
lipid-lowering agents, and they also mediate important
pleiotropic effects, such as improvement of vascular endo-
thelial dysfunction, attenuation of inflammatory responses,
stabilization of atherosclerotic plaques, inhibition of vascu-
lar smooth muscle proliferation, modulation of procoagu-
lant activity, and mobilization of endothelial progenitor
cells (EPCs).9,10
Although the beneficial pleiotropisms by statins are
well documented in a variety of endothelial dysfunc-
tional disorders, their potential therapeutic effects in
maintaining a healthy, usable AV fistula in patients with
DM have not been previously demonstrated. In the
present study, we hypothesized that the endothelial pro-
tective effect of statins may potentiate the vascular func-
tion and flow rate in the AV fistula of rats with diabetes.
METHODS
Animal models and experiments. For expanded
methods, please see the Supplementary Methods (online
only). All procedures were performed in accordance with
the guidelines of the Animal Care and Use Committee of
National Cheng Kung University, Taiwan. The detailed
procedures of creating an aortocaval (AC) fistula have been
described in the previous reports by other research
groups11,12 and modified in our laboratory.13 In brief,
Sprague-Dawley rats (weight, 200-250 g) were anesthe-
tized with inhaled isoflurane (2%-3% v/v in oxygen). After
a midline abdominal incision, the inferior vena cava (IVC)
and aorta were exposed. The aorta was punctured with a
20G disposable needle at the level below the renal vessels.
The needle was gradually introduced across the aorta and
penetrated the neighboring wall of the IVC. The needle
was then withdrawn and the puncturing point at the aorta
was closed by a purse-string suture. A single dose of strep-
tozotocin (65 mg/kg i.p.) was injected to induce type I
diabetes in rats. Hyperglycemia was defined as a random
blood glucose level of more than 200 mg/dL.
Treatment protocol. Rats were randomly allocated
into three groups before the creation of AC fistulas (con-
trol, DM, and DM  rosuvastatin group). Animals in the
rosuvastatin group were fed with rosuvastatin-containing
chow (15 mg/kg/d)14 3 days before the operation and
continued up to 2 weeks after creation of the AC fistulas.
The other experimental animals received only plain chow ihroughout the study period. Plain chow was purchased
rom Harlan Laboratories (Indianapolis, Ind).
Hemodynamic measurements and vasomotor func-
ion assessment. Transthoracic echocardiography (Sonos
500, Ultrasound Systemwith a 12-MHz probe; Agilent Tech-
ologies, Santa Clara, Calif) was performed in anesthetized rats
efore death to evaluate the global myocardial function in ani-
als with or with diabetes and determine the effect of rosuvasta-
in on cardiac performance. Arterial blood pressure in the carotid
rtery was directed measured by connecting to a fluid-filled
ressure transducing system. Blood flow in the arterial site of an
Cfistula was determined using an ultrasonic flowprobe (Tran-
onic System, Ithaca, NY) after exploratory laparotomy.15 All
emodynamic measurements were carried out by investigators
ho were blinded to the treatment groups. Segments of aorta
ere mounted in organ chambers containing Krebs-Ringer bi-
arbonate.Changes in tensionwere recordedcontinuouslyusing
n isometric force-displacement transducer. After a 45-minute
quilibration period, the rings were contracted by addition of
Cl (40 mM) and cumulative addition of phenylephrine
109105M).Concentration-response curveswereobtained
y cumulative addition of acetylcholine during precontracting
he rings with a median effective concentration (EC50) of phen-
lephrine. In some experiments, aortic preparations were prein-
ubated with a cell-permeable superoxide dismutase mimetic
Mn–III-tetrakis-4-benzoicacid-porphyrin;MnTBAP;105M)
efore each contraction.16
Measurement of circulating endothelial progenitor
ells and blood chemistry. Blood was collected immedi-
tely after euthanasia. Blood samples (100L) were stained
ithfluorescentconjugatedantibodiesCD34(phenylephrine-
onjugated; 1:50 dilution, NOVUS Biologicals, Littleton,
olo) and vascular endothelial growth factor receptor-2/
DR (DyLight 488-conjugated; 1:100 dilution; NOVUS
iologicals). Cell fluorescence was measured immediately
nder a flow cytometry (BD FACS Calibur; BD Biosci-
nces, San Jose, Calif).17 Blood glucose, levels of plasma
holesterol, high-density lipoprotein (HDL), and triglycer-
de were analyzed.
Determinations of superoxide anions, cGMP, and
roinflammatory gene expressions. The generation of
uperoxide anions in the blood vessels was measured using
he chemiluminescence and diethedium assays as previously
escribed.16,17 Tissue levels of cyclic guanosinemonophos-
hate (cGMP; the second messenger of nitric oxide [NO])
ere quantified using an enzyme-linked immunosorbent
ssay (R&D Systems, Xindian City, Taipei, Taiwan). The
xpressions of inducible NO synthase (iNOS) and nicotin-
mide adenine dinucleotide phosphate (NADPH) oxidase
n the isolated aorta were determined by Western blot-
ing.16
Histologic sections. Isolated arterial tissue was im-
ersed in 4% formaldehyde for 24 hours. Paraffin-
mbedded tissues were sectioned and stained with hema-
oxylin and eosin (H&E) and Verhoeff stains.13
Statistical analysis. Results are presented as the mean 
D.Datawere comparedby analysis of variance. Statistical signif-
cance was accepted at a level of P .05.
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Blood biochemistry analysis and number of circu-
lating EPCs. The blood glucose level was significantly
increased in rats that received streptozotocin injection, and
administration of rosuvastatin did not affect the blood
glucose level of rats with diabetes (Table). Rosuvastatin
reduced serum concentration of triglyceride and increased
the level of HDL in animals with hyperglycemia, whereas
serum cholesterol levels were similar among all treatment
groups (Table). The number of circulating CD34/
KDR mononuclear cells (defined as EPCs) was reduced
in diabetic animals, but treatment with rosuvastatin signif-
icantly enhanced the number of EPCs in the systemic
circulation (Fig 1).
Hemodynamic measurements. Systemic blood pres-
sure was not different in animals with or without the
development of DM, and neither was the administration of
rosuvastatin (data not shown). The global myocardial func-
tion was also similar in each group (Supplementary Fig,
online only), indicating that rosuvastatin did not affect the
Table. Serum levels of glucose and lipid profiles in contro
Blood chemistry Control
Blood sugar (mg/dL) 199.6  8
Cholesterol (mg/dL) 45.0  2.5
Triglyceride (mg/dL) 44.7  13.7
HDL (mg/dL) 10.3  1.8
DM, Diabetes mellitus; HDL, high-density lipoprotein cholesterol.
Six to eight different animals.
aP  .05 compared with control.
bP  .05 compared with DM group.
Fig 1. Numbers of circulating endothelial progenitor cells
(EPCs; defined as CD34/KDR mononuclear cells) were re-
duced in rats with chronic hyperglycemia and were significantly
enhanced in diabetic animals receiving rosuvastatin treatment.
Dotted line denotes the level of healthy animals without develop-
ment of diabetes or creation of aortocaval (AC) fistula. *P  .05
diabetes mellitus (DM) vs DM rosuvastatin. Five to six different
animals.cardiac performance in animals with chronic hyperglyce- pia. Compared with controls, blood flow measured in the
rterial site of an AC fistula was significantly decreased in
ats with diabetes, but treatment with rosuvastatin restored
he blood flow in the fistula of diabetic animals (Fig 2).
Vasomotor function assessments. Contraction re-
ponses to KCl-induced depolarization and phenylephrine-
ediated 1-receptor stimulation were significantly en-
anced in diabetic rats and were suppressed to the baseline
evels in the DM  rosuvastatin group (Fig 3, A and B).
he impaired endothelium-dependent relaxation response
n rats with diabetes was restored by rosuvastatin treatment
Fig 2, C). Furthermore, the increased contraction and
mpaired relaxation responses in the arterial rings of dia-
etic animals were significantly potentiated by pretreat-
ent with a cell permeable superoxide anion scavenger
nTBAP in the organ bath (Fig 3, B and C).
Generation of superoxide anions and expression of
roinflammatory genes. The level of superoxide anions
n the arterial tissue of an AC fistula was significantly
ugmented in rats with diabetes, and administration of
osuvastatin rectified the generation of tissue superoxide
Fig 4, A). The increased superoxide anions in the vascu-
ature of diabetic animals were also associated with de-
reased tissue concentration of cGMP, and the cGMP
evel was restored by rosuvastatin treatment (Fig 4, B).
dditionally, upregulation of proinflammatory genes
NOS and p47phox in the vascular homogenates of
atients with diabetes was suppressed in animals fed with
osuvastatin (Fig 5).
Histologic examination. Dihydroethidium fluores-
ence density was highly expressed in the vascular rings
solated from rats with chronic hyperglycemia, whereas
ower fluorescence densities were observed in controls and
nimals receiving rosuvastatin therapy (Fig 6, A-C). H&E
taining of aortic rings showed similar microscopic mor-
hology of blood vessel among the three treatment groups
Fig 6, D-F), and Verhoeff staining demonstrated the ab-
ence of thickening intimal layer or deposition of athero-
clerosis in the vessel wall (Fig 6, G-I).
ISCUSSION
Our study demonstrates that blood flow in an AC
stula of rats with diabetes is reduced due to upregulation
f proinflammatory genes and increased generation of su-
diabetic rats
DM DM  rosuvastatin
307  52a 302  44a
50.7  5.5 54.2  5.0
52.3  30.3 24.5  5.2b
5.0  0.0a 14.5  3.9bl anderoxide anions in the vasculature of fistulas. Enteral ad-
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November 20121384 Roan et alministration of a water-soluble 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor rosuvastatin significantly
attenuates the proinflammatory response and potentiates
vascular endothelial function of AC fistulas in diabetic rats,
thereby restoring the blood flow rate in the AC fistula in
these animals. Furthermore, treatment with rosuvastatin
also enhances the mobilization of endothelial progenitors,
which are valid prognostic biomarkers for cardiovascular
outcomes and are important cellular components contrib-
uting to vascular remodeling or vasculogenesis. We antici-
pate that by providing fundamental evidence for applica-
tion of statins, we are establishing a more durable AV fistula
Fig 2. Measurement of blood flow rate in the arterial sit
diabetes mellitus (DM) using a flow probe. Representati
lower panel indicates the pooled data of mean blood
measurement of flow rate during the systolic phase (mL
significantly reduced in animals with diabetes and was po
2 weeks. *P  .05 in comparison to controls and DM in patients with DM. rCompared with patients without diabetes, the access
lood flow was significantly lower in patients with DM
788  580 vs 1054  681 mL/minute; P  .002).6
atients with DM required a longer time until first use of
heir AV fistula than did patients without diabetes (4.4 
.9 vs 2.9  1.6 months, respectively; P  .02).7 Most
ecently, Schinstock et al18 identified that the risk for
educed primary patency of AV fistulas was increased by
iabetes (hazard ratio, 1.54; 95% confidence interval, 1.14-
.07).8 The presence of diabetes is also a strong indepen-
ent predictive factor for reduced initial intra-access blood
ow within 6 months after creation of an AV fistula (odds
n aortocaval (AC) fistula created in rats with or without
od flow tracings are shown on the upper panel, and the
Subfigures in the upper panel represent the real-time
). Blood flow in the arterial site of the AC fistula was
ated in diabetic rats receiving rosuvastatin treatment for
vastatin (Rosu). Four to five different animals.e of a
ve blo
flow.
/min
tentiatio, 3.5; P  .001).19 However, there is currently very
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Volume 56, Number 5 Roan et al 1385limited effective therapeutic strategy in the prevention of
loss of primary patency and improvement of life expectancy
of AV access in patients with diabetes.20 A long-term (up to
987 days) case-control study suggested that patients receiv-
ing statin therapy were associated with a significantly higher
overall primary patency rate of AV fistulas after 1 year
(81.7% vs 66%) and after 2 years (71.5% vs 39.1%).21 On
the other hand, Pisoni et al22 did not detect any beneficial
effects of statins in the improvement of primary fistula
failure and cumulative graft survival rates in patients with
chronic kidney disease after retrospective database review.
Due to a lack of controlled, randomized prospective clinical
trials, it remains clinically controversial whether statins
could provide therapeutic benefits in the outcomes of AV
access, particularly in patients with diabetes. Creation of a
Fig 3. Measurements of isometric force of aorta isolat
diabetes mellitus (DM). A, Maximal contraction response
B, Concentration response curves induced by cumulativ
um-dependent relaxation in response to cumulative addi
and relaxation of the aortic segment isolated from diabet
dismutase (SOD) mimetic MnTBAP and in animals trea
for DM vs control or DM  rosuvastatin. Four to seven
Fig 4. A, Generation of superoxide anions in the aorti
chemiluminescence assay. Level of superoxide anions w
diabetic rats and was attenuated after treatment with ros
messenger of endothelium-derived nitric oxide (NO), cy
with diabetes and were restored after treatment with rosu
DM, Diabetes mellitus.fistula in the rat abdominal aorta and IVC has been charac- cerized as an acceptable experimental model of an AV
stula.11,23,24 In comparison to controls, blood flow in the
rterial limb was reduced by 60% at 2 weeks after creation of
C fistulas in rats with streptozotocin-induced diabetes.
he reduced access blood flow in diabetic rats was associ-
ted with dysfunctional vascular reactivity in the isometric
ension analysis. Contraction responses were significantly
nhanced, whereas the endothelium-dependent relaxation
as significantly impaired in the isolated arterial vessels of
hese animals. Because increased generation of superoxide
nions has been known as one of the major metabolic
actors contributing to vascular endothelial dysfunction in
M,25 we proposed that abnormal vasomotor responses in
he arterial access of diabetic rats was induced by excessive
roduction of regional superoxide anions. In the organ
m the aortocaval (AC) fistula of rats with or without
Cl depolarization and phenylephrine (PE) 1 agonism.
ition of phenylephrine (109105 M). C, Endotheli-
f acetylcholine (109105 M). Impaired contraction
were potentiated after preincubation with a superoxide
ith oral administration of rosuvastatin (Rosu). *P  .05
rent animals in each group.
of an aortocaval (AC) fistula was determined using the
gnificantly increased in the aortic tissue isolated from
atin. B, Contrarily, tissue concentrations of the second
anosine monophosphate (cGMP), were reduced in rats
in. *P .05. Five to six different animals in each group.ed fro
s to K
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cantly attenuated the contraction response to phenyleph-
rine stimulation and potentiated the acetylcholine-
mediated endothelium-dependent relaxation response in
hyperglycemic animals. In addition to functional assess-
ment of vasomotor function, the tissue concentrations of
superoxide anions were directly measured using the chemi-
luminescence and diethedium assays. Thus, these quantita-
tive and qualitative measurements confirmed the increased
production of superoxide anions in the arterial limb of
fistulas isolated from diabetic animals.
The molecular mechanisms of increased superoxide
production were investigated by measuring the protein
expressions of proinflammatory genes. Expressions of
iNOS and NADPH oxidase were significantly upregulated
in the fistula tissue of diabetic animals, indicating the de-
velopment of high inflammatory and oxidative responses in
these vasculatures. Activation of iNOS and NADPH oxi-
dase are the major sources of superoxide generation in the
vascular system.16,26 Furthermore, the tissue content of
cGMP (the second messenger of nitric oxide) was reduced
Fig 5. Expressions of proinflammatory genes in the aor
without diabetes mellitus (DM). Protein expressions of i
subunit of nicotinamide adenine dinucleotide phosphat
arterial tissue of diabetic rats and were significantly suppre
molecular changes were consistent with the generation of
five different animals in each group.in these animals. Collectively, our results verified that the rbnormal vasoreactivity in the vascular access of diabetic
ats was mainly caused by exaggerated generation of super-
xide anions, which in turn neutralized the endothelium-
erived NO or other vasorelaxing factors. Reduced bio-
vailability of endogenous NO might thus provoke the
ontractility and impair the relaxation of isolated arterial
issue.
Statins have been well known for the pleiotropic effects,
hich make them ideal therapeutic candidates for vascular
rotection of AV fistulas in subjects with chronic hypergly-
emia. In the present study, rats were fed with chow con-
aining rosuvastatin 3 days before and continued up to 2
eeks after operation. Rosuvastatin is a hydrophilic statin
hat provides a superior oral bioavailability than most other
tatins.27 Although the vascular protective effects of lipo-
hilic statins have been extensively studied, hydrophilic
tatins can provide preferential anti-inflammatory or other
ntioxidant responses in vivo.28 Administration of rosuvas-
atin reduced the triglyceride and increased HDL levels in
he blood of diabetic rats, but the serum total cholesterol
nd glucose levels were not different. These blood test
e of an aortocaval (AC) fistula isolated from rats with or
ble nitric oxide synthase (iNOS) and p47phox (a major
ADPH] oxidase) were significantly upregulated in the
n animals receiving rosuvastatin (Rosu) treatment. These
roxide anions and vasomotor analysis. *P .05. Four totic sit
nduci
e [N
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cholesterol-lowering effect.
Hemodynamic parameters were determined to exclude
the effect of rosuvastatin on systemic blood pressure and
cardiac performance, which might confound the measure-
ment of blood flow rate in the AC fistula. The most
important finding of the current study was the restoration
of access blood flow rate in rats with diabetes after oral
administration of rosuvastatin, in the absence of changes in
systemic blood pressure andmyocardial contractility. In the
molecular level, expressions of iNOS and NADPH oxidase
and generation of superoxide anions were significantly sup-
pressed in the arterial vessel of rats with diabetes. In addi-
tion, the contraction and endothelium-dependent relax-
ation responses of these isolated blood vessels were
significantly potentiated. The molecular mechanisms re-
sponsible for the improvement of access blood flow are thus
clearly demonstrated, and these findings are closely consis-
tent with the previous study reported by Erdös et al.29 The
authors showed that treatment with rosuvastatin (up to 4
weeks) normalized the NADPH oxidase-dependent super-
oxide generation and restored the dilator responses to
acetylcholine in the basilar artery of Zucker obese rats.29
We further analyzed the morphologic changes of the arte-
rial limb of AC access. The microscopic morphology of
blood vessels was identical with the development of exper-
Fig 6. Representative histologic sections of arterial tissu
anions in the frozen arterial tissue was measured by the
Increased DHE fluorescent (red) densities were detecte
attenuated in diabetic rats treated with rosuvastatin (C
morphology of arterial walls in the three treatment group
significant changes in the intimal layer or formation of neo
Diabetes mellitus.imental diabetes and administration of rosuvastatin, sug- aesting that the functional changes in vasomotor function
ere not derived from the remodeled medial layer. Verhoff
taining also ruled out the hyperplasia or deposition of
therosclerotic plaques in the intimal layer, which could
ffect the regional blood flow and vasoactive responses in
he fistula.
The mobilization of circulating EPCs after treatment
ith rosuvastatin in animals with DM needs further discus-
ion. Compared with sham-operated animals, creation of
n AC fistula did not affect the number of circulating EPCs
t 2 weeks after operation. Due to our experimental design,
ctivation or increased mobilization of bone marrow-
erived endothelial progenitors at the early stages after
reation of an AC fistula could not be obviated. Neverthe-
ess, our results demonstrated that circulating EPCs were
educed in animals with diabetes and were restored in
nimals that received rosuvastatin therapy. These findings
re consistent with previous studies showing that numbers
nd function of circulating EPCs were reduced in patients
ith diabetes,30,31 and treatment with statins increased the
uantity of EPCs in these patients.32,33
Although we did not provide direct evidence for the
ontribution of EPCs in AC fistulas, our study emphasizes
hat quantitative changes in EPCs may provide useful prog-
ostic value in the maturation of AV access. Numbers of
PCs in the circulation have been considered as valuable
aortocaval (AC) fistula. A-C, Generation of superoxide
roethidium (DHE) assay (magnifications 40 to 400).
he tissue isolated from rats with diabetes (B) and were
F, Hematoxylin and eosin (H&E) stain illustrates the
gnifications 40 to 400).G-I, Verhoeff stain shows no
a in the blood vessels (magnifications 40 to 400).DM,e of
dihyd
d in t
). D-
s (ma
intimssessing biomarkers of inflammation and other cardiovas-
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diabetes may thus result in less favorable outcomes of AC
fistulas.
There are several limitations in the interpretation of our
present study. The development of hyperglycemia in rats by
administration of streptozotocin is different from the clin-
ical course of patients with diabetes with hyperglycemia-
related comorbidities, as most of the late diabetic compli-
cations are generally absent in this experimental model.
Furthermore, the creation of a fistula between abdominal
aorta and IVC through needle puncturing is anatomically
distinct from a fistula ordinarily established in the extremity
vessels of patients with ESRD. Nevertheless, animal exper-
iments are useful research tools to improve our understand-
ing of disease mechanisms and provide fundamental pro-
spectives for conducting further clinical trials.
CONCLUSIONS
We provide the first and very important evidence dem-
onstrating that oral administration of rosuvastatin improves
blood flow and endothelial function of AC fistulas in rats
with DM. The improvement in vasomotor function in the
animals with DM resulted from attenuating the activity of
proinflammatory genes in the remodeled vasculature,
thereby reducing the generation of tissue superoxide an-
ions. Our results underscore the vascular protective effects
of rosuvastatin in the AC fistula of diabetic rats and may
thus enhance our ability to prevent and manage vascular
access failure in patients with diabetes with chronic renal
disease.
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Blood flow measurement in the AV fistula. Blood
flow in the abdominal aorta proximal to the AC fistula
(portion of increased blood flow) was measured by an
ultrasonic flow system (2 PSB-series probe; Transonic Sys-
tems, Ithaca, NY). Blood flowmeasurement was performed
immediately before creation of the AC fistula and 2 weeks
later. Flow tracings were recorded for at least 1.5 minutes
and the mean aortic blood flow was analyzed using a data
acquisition system (Power Lab; AD Instruments) when the
mean arterial pressure was controlled at the levels of 80 to
85 mmHg.
Western blot analysis. Aortic segments were minced
and homogenized in lysis buffer. Equal amounts of total
protein (50	100 g) were loaded into polyacrylamide gels
(9-12%) and transferred onto polyvinylidene fluoride mem-
branes. Mouse monoclonal anti-iNOS (1:1,000; BD Trans-
duction Labs, San Jose, Calif) and anti-p47phox (1:1000; BD
Transduction Labs) antibodies were used. After washing, the
membranes were incubatedwith 1:2000 dilution of horserad-
ish peroxidase-linked secondary antibodies. Bands were visu-
alized using enhanced chemiluminescence and quantified by
scanning densitometry (Scion Image, Frederick, Md).
Flowcytometry analysis. Fresh whole blood samples
(100 L) were drawn from experimental rats directly via
inferior vena cava following midline laparotomy. The sam-
ples were stained with fluorescent conjugated antibodies
Supplementary Fig. The cardiac performance was as
ventricular contraction-relaxation cycles at M-mode. T
treatment group at 2 weeks after creation of aortocaval (A
and 75.7 7.0% for controls, diabetes mellitus (DM), an
for each group.for CD34 antibody (PE-conjugated, 1:50 dilution; aOVUS Biologicals) and VEGF receptor-2 (KDR) anti-
ody (DyLight 488-conjugated, 1:100 dilution; NOVUS
iologicals) at room temperature for 20 minutes. Mouse
gG 
-isotype antibody (eBioscience) and rabbit IgG with
yLight 488 conjugation (Epitomics) were used as control
ntibodies. After lysis of the red blood cells with FACSLyse
BD Biosciences) for 15 minutes in the dark, the resulting
amples were centrifuged (1100 rpm for 5 minutes) and
esuspended in 1 mL of PBS. CD34 and KDR are recog-
ized as specific makers of circulating EPCs. Cell fluores-
ence was measured immediately under a flowcytometry
BD FACS Calibur).
Echocardiography. Rats were anesthetized with in-
aled isoflurane and placed on supine position. Trans-
horacic echocardiography was performed immediately
efore surgery and at 2 weeks before sacrifice using
onos S500 (HP, M24214A Ultrasound system) with a
2 MHz probe (Agilent Technologies, Andover, Mass).
he animals were placed in supine position. Parasternal
hort-axis views were obtained with both M-mode and
D echo images.
Left ventricular end-diastolic diameter (LVEDD) and
nd-systolic diameter (LVESD) were measured perpendic-
lar to the long axis of the ventricle at the location of the
apillary muscle insertion site. Left ventricle ejection frac-
ion (LVEF) was calculated automatically by the echocar-
iography system as (LVEDV-LVESV)/LVEDV100%,
here LVEDV is the left ventricular end-diastolic volume
by left ventricular ejection fraction (LVEF) during
were no significant differences in LVEF between each
tula (the calculated LVEFswere 74.9 2.1%, 70.0 2.0%
treated with rosuvastatin, respectively; n 5-6 animalssessed
here
C) fis
d DMnd LVESV is the left ventricle end-systolic volume.
